Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Fixed Combination of Magnesium, Partenium, Andrographis, Co-enzyme Q10 and Riboflavin (PACR) as Prophylactic Treatment for Migraine: a Randomized Controlled Double Blind Study (ParMig Study)

NCT03190044 is registered in ClinicalTrials.gov with University of Roma La Sapienza as lead sponsor.

NCT NCT03190044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03190044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Fixed Combination of Magnesium, Partenium, Andrographis, Co-enzyme Q10 and Riboflavin (PACR) as Prophylactic Treatment for Migraine: a Randomized Controlled Double Blind Study (ParMig Study)
Lead sponsor
University of Roma La Sapienza
Phase
Not applicable
Overall status
Unknown status
Start date
June 6, 2017
Completion date
December 31, 2019
Enrollment
82 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

migraine disorders